Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Consensus Target Price from Analysts

Celcuity Inc. (NASDAQ:CELC) has received a consensus rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $29.17.

Several brokerages recently issued reports on CELC. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Stifel Nicolaus increased their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Celcuity during the third quarter worth about $33,000. Prospera Private Wealth LLC purchased a new stake in shares of Celcuity in the 3rd quarter worth about $35,000. Values First Advisors Inc. bought a new stake in shares of Celcuity during the 3rd quarter valued at about $86,000. Quest Partners LLC increased its position in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the period. Finally, SG Americas Securities LLC bought a new position in Celcuity in the third quarter worth about $119,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 1.0 %

Shares of CELC opened at $12.53 on Friday. Celcuity has a 1-year low of $11.51 and a 1-year high of $22.19. The company has a market capitalization of $465.24 million, a P/E ratio of -4.80 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The firm’s 50 day simple moving average is $14.03 and its 200 day simple moving average is $15.38.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.